Good vision, minimal disturbances achieved with presbyopia IOL

Article

84% of the patients who received a hybrid, acrylic IOL with a continuous transitional focus (CTF) optic to correct presbyopia were within 0.5 D of emmetropia.

Reviewed by Dr Mike P. Holzer.

Good vision, minimal disturbances achieved with presbyopia IOL

Bilateral implantation of the Precizon Presbyopic NVA Multifocal IOL (Ophtec) provides “satisfying” uncorrected vision at all distances for patients undergoing cataract surgery or clear lens extraction, according to Dr Mike P. Holzer, an ophthalmologist in private practice in Weinheim, Germany.

The company describes this technology as a hybrid, acrylic IOL with a continuous transitional focus (CTF) optic to correct presbyopia, which according to Dr Holzer is a key feature of this IOL. CTF provides seamless transition from one distance to another. The lens is not currently approved by the FDA.

The lens is available in powers ranging from +1.0 to +35.0 D in 0.5-D increments, with an add-on power of +2.75 D. The lens was evaluated in a multicentre, prospective, open-label, single-arm clinical trial (NCT02409771) that looked at the base 10 logarithm of the minimum angle of resolution (logMAR) corrected and uncorrected visual acuity (VA) scores at distance, intermediate, and near; the manifest refraction spherical equivalent; and the defocus curve. Fifty-nine patients were included in the study. All patients in the study underwent bilateral implantation of the IOL.

The results showed that 84% of the patients were within 0.5 D of emmetropia. The investigators observed a slight hyperopic shift. Therefore the constants for the IOL calculation were adjusted. The mean bilateral uncorrected VAs were 0.0 for distance, 0.14 for intermediate, and near 0.2 for near logMAR.

When asked about visual disturbances, most of the patients reported never or almost never having glare or halos. When these visual disturbances did occur, patients reported that they were not bothersome.

“All surgeries for implantation of the IOL were uneventful. The IOL provided very good [VAs] at all distances from far to near. Low percentages of halo and glare occurred. The Precizon Presbyopic IOL implantation is an effective method to provide good [VA] at all distances in presbyopic and cataract patients,” Dr Holzer concluded.

Mike P. Holzer, MD
E: info@augenzentrum-holzer.de
This article is adapted from Dr Holzer’s presentation at the 2022 American Society of Cataract and Refractive Surgery’s Annual Meeting in Washington, DC. The study he presented was supported by Ophtec BV, Groningen, the Netherlands.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.